Update on OnCore Clinical Trial Management System
Posted in Announcement
Among the collaborations between MedStar Health and Georgetown University Medical Center has been the development of a Clinical Trial Management System (CTMS) that not only captures data, but allows for continuity of data and adheres to current billing and compliance regulations. Many of you have shared your desire for an efficient system that allows for more data sharing amongst both organizations.
You may recall that a little over a year ago we completed an extensive review of CTMS software packages and were very pleased to announce the selection of Oncore as our enterprise-wide CTMS. By serving as a workflow manager and repository of all clinical research administrative and management activities, OnCore will greatly enhance and standardize our clinical trial management activities. In addition, it will provide real-time analytics and reporting capabilities about our research activity across the system.
We wanted to take a moment to update you on the progress we have made in implementing OnCore. Last fall, we launched two pilots and since that time we have been putting new studies into the system and migrating current studies over. We have also been training primary end users such as clinical research coordinators, regulatory coordinators and budget/coverage analysts to allow these individuals more time to learn and adapt to the new system. We anticipate that all active clinical trial protocols and research participants will be managed in OnCore by the end of the academic year.
We are thrilled to offer a tool that will manage multiple aspects of your clinical research and in the end, make your data management easier and ensure greater productivity to the work you do in conducting clinical trials. The selection and implementation of the OnCore system is a result of your feedback on the need for a more efficient and accurate collection of clinical trial research data. It also represents a significant commitment and investment by MedStar Health and GUMC.
We thank you for your commitment to discovering new treatments and helping to advance medicine.